Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, announced the successful closing of a US$11.6 million Series A financing round led by We Venture Capital and ClavystBio. The round also had participation from Adaptive Capital Partners, conversion of note securities from Mayo Clinic’s Mayo Foundation for Medical Research and from existing investors including Greenwillow Capital Management, Seeds Capital, and she1K angel investment. Proceeds will support expansion of Respiree’s commercial team and U.S. presence, including company headquarters in Houston, Texas, at the Texas Medical Center (TMC) Innovation.
“The digitalization of healthcare offers a powerful opportunity to improve outcomes and efficiency—but without the right tools, it risks overwhelming care systems, especially amid workforce shortages,” said Dr. Gurpreet Singh, Founder and CEO of Respiree. “What we need is better use of data, not just more data. Our AI solutions enable timely interventions, reduce alarm fatigue, and support care quality. We’re now focused on scaling these tools to enhance the entire patient journey—from smarter triage to follow-up.”
Respiree’s innovative, augmented-AI platform seeks to support quicker, efficient and precise decision making in various healthcare settings by automating patient monitoring, care pathway management and clinical insight delivery. One of its flagship AI models developed during the Mayo Clinic Platform_Accelerate program, where Respiree graduated from, can help healthcare professionals detect patient deterioration earlier – including rapid response calls in general wards and unplanned ICU transfers. Published as a pre-print in The Lancet, this flagship AI model significantly reduced false alarms while maintaining strong sensitivity — outperforming the positive predictive value (PPV) of EPIC’s deterioration index by a factor of six (54.9% vs 8%). Respiree is currently in the process of seeking clearance from the US Food and Drug Administration (FDA) for its flagship AI model. The goal is to integrate the model into its platform, 1Bio™, which already incorporates data from electronic health records (EHRs), mobile questionnaires, third party devices and Respiree’s proprietary, U.S.-patented, FDA-cleared sensors to provide longitudinal insights into disease trajectories.
Also Read: ScienceSoft Raises the Bar for AI Voice Scheduling in Healthcare
“We are very proud to welcome Respiree to the We VC portfolio,” said Louise Warme, Head of We Venture Capital. “Respiree stands out in the market by providing a patient monitoring AI/ML + hardware solution with incredible performance, but also unmatched understanding and execution of clinical workflow integration. Their scientifically validated data and key partnerships position Respiree for a promising scale-up journey driven by an extremely execution-focused team.”
“ClavystBio’s investment in Respiree is central to our strategy of helping companies scale globally from and through Singapore. Their innovative AI-powered monitoring platform is set to enhance patient care and empower clinical teams with actionable insights. This further underscores our commitment to accelerating medtech innovations aimed at improving patient outcomes across care settings,” said Anselm Tan, Digital Health & MedTech Lead, ClavystBio.
Respiree’s current solutions include:
- Scalable AI modules designed to be device-agnostic, platform independent and EHR-compatible, with increased precision to identify patient deterioration across patient touchpoints with low false alarms
- Pathway-management modules designed to automate delivery of standardized care pathways and requirements for nurses and patients to execute
- Centralized, EHR-agnostic platform connected to a broad range of EHR environments and medical device systems, consolidating continuous real-time analytics and data from multiple sources
- Connected wearables with configurable acquisition settings for a range of use-cases, capable of capturing a broad range of cardio-respiratory measures
“Respiree has achieved much since Greenwillow Capital Management first invested in February 2022 and continued to support the Company in the convertible notes last year. We are incredibly encouraged by the commercialization of Respiree’s products and services in tier-one markets and look forward to being part of Respiree’s growth as it continues to transform patient care on a global scale. We very much welcome the new investors We VC, ClavystBio and Adaptive Capital and look forward to working together in Respiree’s forward journey,” said Dr. Wong Mun Yew, Managing Partner of Oriza Greenwillow Technology Fund.
Source: Globenewswire
